AB
XLO icon

Amalgamated Bank’s Xilio Therapeutics XLO Stock Holding History

Amalgamated Bank’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-77
Closed -$8K – 3220
2022
Q1 		$8K Buy
+77
New +$12.2K ﹤0.01% 2996

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Amalgamated Bank's XLO Position: Q2 2022 in Review

Amalgamated Bank sold out of Xilio Therapeutics (XLO) in Q2 2022, closing a stake of 77 shares — an estimated $8K sold.

Amalgamated Bank first reported a position in XLO in Q1 2022 and held it in 1 quarter. The position peaked at $8K in Q1 2022. 32 funds tracked by Wall St. Rank hold XLO as of Q2 2022.

  • Amalgamated Bank reported no remaining Xilio Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Amalgamated Bank sold 77 Xilio Therapeutics shares in Q2 2022, an estimated $8K.
  • Amalgamated Bank first reported a position in Xilio Therapeutics in Q1 2022 and held it in 1 quarter.
  • Amalgamated Bank's Xilio Therapeutics position peaked at $8K in Q1 2022.
  • 32 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q2 2022.

Based on Amalgamated Bank's 13F filing for Q2 2022, filed 15 Aug 2022.